Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Pacific Edge’s half year report

Please find attached Pacific Edge’s half year report

--

Highlights and Key Events

• Signed Cxbaldder agreement with Multiplan, a large National Provider Network (NPN) in the US. This is the fourth agreement to be signed with NPNs since October 2013.

• Signed User Programme agreement with Southern California Permanente Medical Group (SCPMG) to trial and evaluate Cxbladder within the clinical settings of Kaiser Permanente’s health care network.

• Expanded US sales team from four to twelve members.

• Launched ecommerce platform in New Zealand, making Cxbladder test easily accessible by New Zealand urologists, physicians and patients.

• Successfully completed two validation studies with the Waitemata and Canterbury District Health Boards with results supporting clinical study findings.

• Signed agreements with Urologists servicing the Bay of Plenty and Lakes District Health Boards.

• Continuing to work with National Health Council to put Cxbladder into the Standard of Care in New Zealand.

• Pacific Edge granted US patent for melanoma prognostic technology in the US.

• Pacific Edge granted patent in Japan for colorectal cancer prognostic technology.

• Named NZBIO’s top Bioscience company for 2014 for building the profile and credibility of biotechnology and biotechnology companies in New Zealand.

• Continuing the refresh of the Pacific Edge Board with the resignation of Colin Dawson following the 2014 annual meeting and the appointment of Charles Sitch as an independent director, effective from 1 November 2014.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

CEO, David Darling was appointed as Executive Director at the annual meeting.

Post-period end:

• Announced appointment of Kate Rankin as Chief Financial Officer.

• Launched Cxbladder Triage in New Zealand and Australia, providing a new tool for urologists and clinicians to triage out patients presenting with haematuria who have a low probability of having bladder cancer.

PELHYREPORTDEC14NZXANNOUNCEFINAL16Dec14.pdf

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.